Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jul
09
Today In Oncology
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo